/BPMC

BPMC Stock - Blueprint Medicines Corporation

Q: What is the analyst price target for BPMC?

Analyst price target information is not currently available for BPMC.

Q: What is BPMC's market cap?

Market capitalization information is not currently available for BPMC.

Healthcare|Biotechnology|NASDAQ

$129.46+0.14%

+$0.18 (+0.14%) • Jul 18

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+8.9%upside

Target: $140.98

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BPMC

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.83

52W High$129.55

52W Low$73.04

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$508.82M	$249.38M	$204.04M	$180.08M	$793.74M
Gross Profit	$488.66M	$236.58M	$186.22M	$162.15M	$793.31M
Gross Margin	96.0%	94.9%	91.3%	90.0%	99.9%
Operating Income	$-212,044,000	$-486,277,000	$-549,253,000	$-648,460,000	$302.15M
Net Income	$-67,089,000	$-506,984,000	$-557,517,000	$-644,085,000	$313.88M
Net Margin	-13.2%	-203.3%	-273.2%	-357.7%	39.5%
EPS	$-1.07	$-8.37	$-9.35	$-11.01	$5.76

Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

60%

Hold / Neutral

27%

Sell / Underperform

13%

Analyst Consensus🟡 Mixed

9 Bullish6 Neutral/Bearish

Price Targets

$88

Average Target

↓ 32.1% Downside

Now

$40

Low

$88

Average

$150

High

Based on 19 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
June 2nd 2025	Wedbush	Downgrade	Neutral	$129
March 20th 2025	Morgan Stanley	Resumed	Equal Weight	$100
March 18th 2025	Wolfe Research	Initiation	Outperform	-
March 17th 2025	Jefferies	Initiation	Buy	$135
March 7th 2025	Scotiabank	Initiation	Sector Outperform	$150
November 14th 2024	JP Morgan	Initiation	Overweight	$126
October 24th 2024	UBS	Initiation	Neutral	$88
May 14th 2024	Stephens	Initiation	Overweight	$140
May 6th 2024	Leerink Partners	Upgrade	Market Perform	$97← $50
October 27th 2023	Oppenheimer	Upgrade	Outperform	$85
August 21st 2023	Needham	Reiterated	Buy	$66← $65
July 31st 2023	Wells Fargo	Upgrade	Overweight	$82← $55
June 5th 2023	SVB Securities	Downgrade	Underperform	$43← $48
January 3rd 2023	Wells Fargo	Upgrade	Equal Weight	$41
December 14th 2022	Needham	Initiation	Buy	$60

Earnings History & Surprises

BPMC

Beat Rate

60%

Last 20 quarters

Avg Surprise

-0.1%

EPS vs Estimate

Beats / Misses

12/7

1 met exactly

Latest EPS

$-0.74

Q2 2025

EPS Surprise History

Q3 23

+15.1%

$-2.19vs$-2.58

Q4 23

+7.9%

$-2.20vs$-2.39

Q1 24

+10.8%

$-1.82vs$-2.04

Q2 24

+19.5%

$-1.32vs$-1.64

Q3 24

+37.5%

$-0.80vs$-1.28

Q4 24

+8.2%

$-0.89vs$-0.97

Q1 25

-16.2%

$-0.79vs$-0.68

Q2 25

-76.2%

$-0.74vs$-0.42

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	May 1, 2025	$-0.42	$-0.74	-76.2%	✗ MISS
Q1 2025	Feb 13, 2025	$-0.68	$-0.79	-16.2%	✗ MISS
Q4 2024	Oct 30, 2024	$-0.97	$-0.89	+8.2%	✓ BEAT
Q3 2024	Aug 1, 2024	$-1.28	$-0.80	+37.5%	✓ BEAT
Q2 2024	May 2, 2024	$-1.64	$-1.32	+19.5%	✓ BEAT
Q1 2024	Feb 15, 2024	$-2.04	$-1.82	+10.8%	✓ BEAT
Q4 2023	Oct 26, 2023	$-2.39	$-2.20	+7.9%	✓ BEAT
Q3 2023	Aug 2, 2023	$-2.58	$-2.19	+15.1%	✓ BEAT
Q2 2023	May 4, 2023	$-2.66	$-2.15	+19.2%	✓ BEAT
Q1 2023	Feb 16, 2023	$-2.73	$-2.65	+2.9%	✓ BEAT
Q4 2022	Nov 1, 2022	$-2.51	$-2.23	+11.2%	✓ BEAT
Q3 2022	Aug 2, 2022	$-2.23	$-2.68	-20.2%	✗ MISS
Q2 2022	May 3, 2022	$-1.79	$-1.79	0.0%	= MET
Q1 2022	Feb 16, 2022	$-0.71	$-0.99	-39.4%	✗ MISS
Q4 2021	Oct 28, 2021	$-1.69	$-2.00	-18.3%	✗ MISS
Q3 2021	Jul 29, 2021	$-1.77	$-1.86	-5.1%	✗ MISS
Q2 2021	Apr 29, 2021	$-1.80	$-1.72	+4.4%	✓ BEAT
Q1 2021	Feb 17, 2021	$-1.57	$-1.53	+2.5%	✓ BEAT
Q4 2020	Oct 29, 2020	$7.72	$11.16	+44.6%	✓ BEAT
Q3 2020	Jul 30, 2020	$-2.08	$-2.28	-9.6%	✗ MISS

Frequently Asked Questions about BPMC

What is BPMC's current stock price?

Blueprint Medicines Corporation (BPMC) is currently trading at $129.46 per share. The stock has moved +0.14% today.

What is the analyst price target for BPMC?

The average analyst price target for BPMC is $141.00, based on 1 analyst.

What sector is Blueprint Medicines Corporation in?

Blueprint Medicines Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is BPMC's market cap?

Blueprint Medicines Corporation has a market capitalization of $8.36 billion, making it a mid-cap company.

Does BPMC pay dividends?

No, Blueprint Medicines Corporation does not currently pay a dividend to shareholders.